ArticleEuropean journal of neurology2025
Intraepineurial Fat Fraction: A Novel MR Neurography-Based Biomarker in Transthyretin Amyloidosis Polyneuropathy.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHereditary transthyretin amyloid polyneuropathy (ATTRv-PN) is a rare and progressive neurodegenerative disorder characterized by axonal neuropathy and amyloid deposits. Early detection of disease onset and progression is crucial for timely therapeutic intervention. Quantitative MRI (qMRI) can be used to measure potential biomarkers. Intraepineurial fat fraction (ieFF) may reflect lipid droplets in amyloid deposits as described in histological studies or the replacement of nerve fiber loss with fatty-rich interfascicular epineurium. This study investigates the potential utility of ieFF as a novel imaging-related biomarker in differentiating ATTRv-PN, asymptomatic carriers (ATTRv-C), and healthy controls (HCs).
methodsFifty-three patients with TTR mutations were imaged (31 ATTRv-PN patients, 22 ATTRv-C, and 24 HC) and both clinical and electrophysiological parameters were quantified. 3D volume, ieFF, and magnetization transfer ratio (MTR) were quantified in sciatic and tibial nerves using qMRI.
resultsSymptomatic ATTRv-PN patients exhibited significantly higher ieFF in both sciatic (32.4% IQR [24.4-38.1]) and tibial nerves (13.7%, IQR [9.97-20.7]) compared to controls (sciatic 22.3%, IQR [16.6-28.5]; tibial 9.74%, IQR [6.36-12.5]) (p < 0.05). ieFF values were positively correlated in both uni and multivariate analyses with the main clinical scores and electrophysiological measures. ATTRv-C also showed increased ieFF values compared to controls (p < 0.05). Comparatively, MTR and nerve volumes exhibited less pronounced differences across groups.
conclusionThis study demonstrates that ieFF effectively differentiates symptomatic and asymptomatic ATTRv patients from HC and correlates strongly with electrophysiological and clinical severity parameters. Furthermore, we compare ieFF with conventional qMRI biomarkers, highlighting its superior potential for monitoring nerve structural impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.